Skip to main
BDX

BDX Stock Forecast & Price Target

BDX Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 33%
Buy 20%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Becton Dickinson is poised for future growth with a focus on high-growth platforms and shareholder returns, but challenges in certain areas could delay organic growth. The recent split to become a pure-play MedTech company and use of cash proceeds for shareholder returns show strong commitment to driving shareholder value. However, external factors and changes in healthcare delivery pose potential risks to long-term performance.

Bears say

Becton Dickinson is a global healthcare company focused on four business units, including medical essentials, connected care, biopharma systems, and interventional. The company has a negative outlook due to concerns over the impact of the COVID-19 pandemic and potential future headwinds in its core businesses. Despite strong diversity efforts and key initiatives in sustainability and environmental impact, Becton Dickinson may face challenges in achieving consistent MSD growth and its stock re-rating likely requires proof of this growth in the upcoming fiscal year.

BDX has been analyzed by 15 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 20% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Becton, Dickinson and Co. (BDX) Forecast

Analysts have given BDX a Buy based on their latest research and market trends.

According to 15 analysts, BDX has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $188.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $188.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Becton, Dickinson and Co. (BDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.